ChromaVision/Ventana to market HPV (Human Papilloma Virus) test:
This article was originally published in Clinica
Executive Summary
ChromaVision Medical Systems and Ventana Medical Systems are to co-market an automated staining and imaging test for human papillomavirus. The test will combine ChromaVision's automated cellular imaging system (ACIS) and Ventana's automated staining systems and reagents to offer direct visual interpretation of cellular analyses. Until now ChromaVision has concentrated on oncologic tests. It is estimated that the US market alone is some 3.5 million HIV tests per year.